Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs

Eleftheria Galatou; Elena Mourelatou; Sophia Hatziantoniou; Ioannis S. Vizirianakis

doi:10.3390/antiox11061060

Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs

Eleftheria Galatou, Elena Mourelatou, Sophia Hatziantoniou, Ioannis S. Vizirianakis

School of Life and Health Sciences

Research output: Contribution to journal › Review article › peer-review

Abstract

Nonalcoholic steatohepatitis (NASH) is the most severe manifestation of nonalcoholic fatty liver disease (NAFLD), a common complication of type 2 diabetes, and may lead to cirrhosis and hepatocellular carcinoma. Oxidative stress and liver cell damage are the major triggers of the severe hepatic inflammation that characterizes NASH, which is highly correlated with atherosclerosis and coronary artery disease. Regarding drug therapy, research on the role of GLP-1 analogues and DPP4 inhibitors, novel classes of antidiabetic drugs, is growing. In this review, we outline the association between NASH and atherosclerosis, the underlying molecular mechanisms, and the effects of incretin-based drugs, especially GLP-1 RAs, for the therapeutic management of these conditions.

Original language	English
Article number	1060
Journal	Antioxidants
Volume	11
Issue number	6
DOIs	https://doi.org/10.3390/antiox11061060
Publication status	Published - Jun 2022

Keywords

atherosclerosis
cardiovascular outcome trial (CVOT)
DPP4-i
GLP-1 RAs
incretin-based drugs
inflammation
lipotoxicity
nonalcoholic fatty liver disease (NAFLD)
nonalcoholic steatohepatitis (NASH)
oxidative stress

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/antiox11061060

Cite this

@article{73a49c1547a34ae79df8158986c314d5,

title = "Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs",

abstract = "Nonalcoholic steatohepatitis (NASH) is the most severe manifestation of nonalcoholic fatty liver disease (NAFLD), a common complication of type 2 diabetes, and may lead to cirrhosis and hepatocellular carcinoma. Oxidative stress and liver cell damage are the major triggers of the severe hepatic inflammation that characterizes NASH, which is highly correlated with atherosclerosis and coronary artery disease. Regarding drug therapy, research on the role of GLP-1 analogues and DPP4 inhibitors, novel classes of antidiabetic drugs, is growing. In this review, we outline the association between NASH and atherosclerosis, the underlying molecular mechanisms, and the effects of incretin-based drugs, especially GLP-1 RAs, for the therapeutic management of these conditions.",

keywords = "atherosclerosis, cardiovascular outcome trial (CVOT), DPP4-i, GLP-1 RAs, incretin-based drugs, inflammation, lipotoxicity, nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), oxidative stress",

author = "Eleftheria Galatou and Elena Mourelatou and Sophia Hatziantoniou and Vizirianakis, {Ioannis S.}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jun,

doi = "10.3390/antiox11061060",

language = "English",

volume = "11",

journal = "Antioxidants",

issn = "2076-3921",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "6",

}

TY - JOUR

T1 - Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis

T2 - Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs

AU - Galatou, Eleftheria

AU - Mourelatou, Elena

AU - Hatziantoniou, Sophia

AU - Vizirianakis, Ioannis S.

PY - 2022/6

Y1 - 2022/6

N2 - Nonalcoholic steatohepatitis (NASH) is the most severe manifestation of nonalcoholic fatty liver disease (NAFLD), a common complication of type 2 diabetes, and may lead to cirrhosis and hepatocellular carcinoma. Oxidative stress and liver cell damage are the major triggers of the severe hepatic inflammation that characterizes NASH, which is highly correlated with atherosclerosis and coronary artery disease. Regarding drug therapy, research on the role of GLP-1 analogues and DPP4 inhibitors, novel classes of antidiabetic drugs, is growing. In this review, we outline the association between NASH and atherosclerosis, the underlying molecular mechanisms, and the effects of incretin-based drugs, especially GLP-1 RAs, for the therapeutic management of these conditions.

AB - Nonalcoholic steatohepatitis (NASH) is the most severe manifestation of nonalcoholic fatty liver disease (NAFLD), a common complication of type 2 diabetes, and may lead to cirrhosis and hepatocellular carcinoma. Oxidative stress and liver cell damage are the major triggers of the severe hepatic inflammation that characterizes NASH, which is highly correlated with atherosclerosis and coronary artery disease. Regarding drug therapy, research on the role of GLP-1 analogues and DPP4 inhibitors, novel classes of antidiabetic drugs, is growing. In this review, we outline the association between NASH and atherosclerosis, the underlying molecular mechanisms, and the effects of incretin-based drugs, especially GLP-1 RAs, for the therapeutic management of these conditions.

KW - atherosclerosis

KW - cardiovascular outcome trial (CVOT)

KW - DPP4-i

KW - GLP-1 RAs

KW - incretin-based drugs

KW - inflammation

KW - lipotoxicity

KW - nonalcoholic fatty liver disease (NAFLD)

KW - nonalcoholic steatohepatitis (NASH)

KW - oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=85131187060&partnerID=8YFLogxK

U2 - 10.3390/antiox11061060

DO - 10.3390/antiox11061060

M3 - Review article

AN - SCOPUS:85131187060

SN - 2076-3921

VL - 11

JO - Antioxidants

JF - Antioxidants

IS - 6

M1 - 1060

ER -

Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this